MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
4.710
-0.030
-0.63%
Closed 19:42 01/27 EST
OPEN
4.680
PREV CLOSE
4.740
HIGH
4.990
LOW
4.462
VOLUME
106.45K
TURNOVER
--
52 WEEK HIGH
7.41
52 WEEK LOW
2.000
MARKET CAP
190.55M
P/E (TTM)
-1.8741
1D
5D
1M
3M
1Y
5Y
SLRX, CNET and WISA among mid-day movers
Seeking Alpha · 01/20 18:18
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/17 21:31
BLI, SRGA and UPLD are among after hour movers
Seeking Alpha · 01/12 23:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/12 21:31
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/07/2022 21:32
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability With CDK 4/6 Inhibitor Palbociclib In Phase 1b Dose Escalation Study
Benzinga · 12/07/2022 20:39
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER ...
GlobeNewswire · 11/21/2022 14:16
Olema Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY
Benzinga · 11/08/2022 22:12
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It is designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It is in the Phase I/ IIclinical trial, and in Phase I combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Webull offers kinds of Olema Pharmaceuticals Inc stock information, including NASDAQ:OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.